On the stock market since 2004, it operates in the world of health and science. It has 476 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
Sales run at $41.4M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 5 buys and 1 sell. Management buying with its own money is usually read as a good sign.
It pays out $0.40 per share each year — regular cash for whoever holds the stock.
A loss of $1.0M against $41.4M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, GBCS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GBCS is a high-risk stock — not yet profitable, and its future rides on its product catching on.